Clinical study of adefovir dipivoxil combined with thymosin α1 on treatment of lamivudine-resistant chronic hepatitis B

Objectives: To investigate the clinical curative effect in adefovir dipivoxil combined with thymosin α1 in the treatment of lamivudine-resistant chronic hepatitis B. Methods: One huandred and fifty eight patients in our hospital from January 2007 to September 2011 with lamivudine resistance in chronic hepatitis B were randomly divided into 2 groups, used separate adefovir dipivoxil (10 mg/d, continuous treatment for 48 weeks) treatment of patients as control group of 78 cases, with adefovir dipivoxil (10 mg/d, continuous treatment for 48 weeks) combined with thymosin α1 (subcutaneous injection of 1.6 mg/time, 2 times a week, continuous treatment for 48 weeks) treatment of the patient as the observation group of 80 cases, were detected in patients with each index and comparative analysis. Results: The observation group ALT recovery, HBV-DNA negative cases, HBeAg negative cases, HBe seroconversion in patients after 24 weeks and 48 weeks treatment was significantly better than the control group, there was significant difference (P0.05). Conclusion: Adefovir dipivoxil combined with thymosin α1 in treatment of lamivudine-resistant chronic hepatitis B has curative clinical effect, is worthy of clinical application.